Research Article
Benefits of On-X Mitral Valve Replacement in Cases of Infective Endocarditis
Table 3
Operative and post-operative variables among the total patients and per study group.
| | | Total | On-X group | SJM group | value | | (n = 40) | (n = 13) | (n = 27) |
| | Operation time (minutes) | 307.6 ± 86.3 | 288.2 ± 53.1 | 318.1 ± 99.3 | 0.4939 | | Aortic cross-clamp time (minutes) | 115.4 ± 43.8 | 108.0 ± 24.4 | 119.2 ± 50.8 | 0.5412 | | Cardiopulmonary bypass time (minutes) | 140.3 ± 54.7 | 133.0 ± 32.2 | 143.9 ± 63.4 | 0.5912 | | Size of prosthetic valves | | On-X 25 mm | 2 (5.0) | 2 (15.4) | N/A | | | On-X 27/29 mm | 4 (10.0) | 4 (30.8) | N/A | | | On-X 31/33 mm | 7 (17.5) | 7 (53.8) | N/A | | | SJM 25 mm | 4 (10.0) | N/A | 4 (14.8) | | | SJM 27 mm | 14 (35.0) | N/A | 14 (51.9) | | | SJM 29 mm | 7 (17.5) | N/A | 7 (25.9) | | | SJM 31 mm | 2 (5.0) | N/A | 2 (7.4) | | | Orifice area (cm2) | 4.0 ± 0.5 | 4.1 ± 0.0 | 3.9 ± 0.6 | 0.0770 | | Body surface area (m2) | 1.6 ± 0.2 | 1.6 ± 0.2 | 1.6 ± 0.2 | 0.4578 | | Associated procedure | | CABG | 0 (0.0) | 0 (0.0) | 0 (0.0) | >0.9999 | | Aortic valve replacement | 1 (2.5) | 1 (7.7) | 0 (0.0) | 0.3250 | | Tricuspid repair | 12 (30.0) | 0 (0.0) | 12 (44.4) | 0.0005 | | Post-operative hospital stay (days) | 36.4 ± 27.6 | 45.5 ± 36.4 | 31.7 ± 21.0 | 0.2124 | | In-hospital mortality | 0 (0.0) | 0 (0.0) | 0 (0.0) | >0.9999 | | Late mortality | 6 (15.0) | 0 (0.0) | 6 (22.2) | 0.1520 | | Overall mortality | 6 (15.0) | 0 (0.0) | 6 (22.2) | 0.1520 | | Reintervention | 4 (10.0) | 1 (7.7) | 3 (11.1) | >0.9999 | | Recurrent mitral regurgitation | 7 (17.5) | 3 (23.1) | 4 (14.8) | 0.6622 | | Atrial fibrillation in late phase | 11 (27.5) | 1 (7.7) | 10 (37.0) | 0.0678 | | Biochemistry blood test in late phase | | LDH (IU/L) | 315.1 ± 101.3 | 309.7 ± 119.8 | 317.6 ± 93.5 | 0.5442 |
|
|
Values are mean ± SD or n (%). CABG coronary artery bypass grafting, LDH lactate dehydrogenase, SJM St. Jude Medical.
|
